AUG 10, 2026 · JOURNAL ARTICLE
Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study
Bladder Cancer
A sound but limited retrospective multicenter study of a bladder-preserving therapy in BCG-failed NMIBC, with meaningful recurrence-free survival rates but modest sample size and no comparator arm.
Reported
Median follow-up38 months (IQR 21–55)
Intravesical recurrence rate36.9%
1-year intravesical RFS77.9%